You are here

Herman Staats

Research Interest: 
Microbiology and virology
Research Summary: 
Development of vaccine adjuvants and vaccination methods to deliver vaccines by mucosal routes without the use of needles.
Research Description: 

Most vaccines used in human medicine are delivered by a needle injection. While injection of vaccines is effective, the use of needles in developing countries often leads to the re-use of needles and disease transmission due to the use of dirty needles. Immunization by a mucosal route, such as intranasal or oral, can be performed without the use of needles. Research in the Staats' lab focuses on the development of safe and effective mucosal vaccination strategies. Specific areas of research include the development of vaccine adjuvants that are required for induction of protective immune responses after mucosal immunization.

Stable dry powder formulation for nasal delivery of anthrax vaccine.
Wang SH, Kirwan SM, Abraham SN, Staats HF, Hickey AJ.
J Pharm Sci. 2012. 101:31-47.

Cytokines: the future of intranasal vaccine adjuvants.
Thompson AL, Staats HF.
Clin Dev Immunol. 2011. 2011:289597.

Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits.
Staats HF, Fielhauer JR, Thompson AL, Tripp AA, Sobel AE, Maddaloni M, Abraham SN, Pascual DW.
PLoS One. 2011. 6:e16532.

Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.
Gwinn WM, Kirwan SM, Wang SH, Ashcraft KA, Sparks NL, Doil CR, Tlusty TG, Casey LS, Hollingshead SK, Briles DE, Dondero RS, Hickey AJ, Foster WM, Staats HF.
Vaccine. 2010. 28:6901-14.

Mast cell activators: a new class of highly effective vaccine adjuvants.
McLachlan JB, Shelburne CP, Hart JP, Pizzo SV, Goyal R, Brooking-Dixon R, Staats HF, Abraham SN.
Nat Med. 2008. 14:536-41.